U.S., April 12 -- ClinicalTrials.gov registry received information related to the study (NCT06923592) titled 'Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar' on April 03.
Brief Summary: The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria (relapses) and ongoing parasite transmission. Relapses account for a majority of recurrent infections and clinical cases of P. vivax malaria, and therefore have a significant effect on morbidity at the individual level.
With current technology, it is not possible to directly measure hypno...